RAF1 Amplification

CI-VAR-00000219Explore in graph →CIViC 591

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
RAF1 Amplification	B-Raf/VEGFR-2 Inhibitor RAF265 + TrametinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID11767 In this pre-clinical study, RAF inhibition and RAF inhibition in combination with MEK inhibition was tested in vivo in RAF1-amplified tumors (in both mice and PDX tumor models). The models were treate… (full text at CIViC) PMID 34554931 · Bekele et al., 2021 · Open in CIViC	civic
Cutaneous Melanoma1
RAF1 Amplification	Carboplatin + Paclitaxel + SorafenibCombination	Predictive	B	Supports Sensitivity Response	2	accepted

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Hepatocellular Carcinoma1
RAF1 Amplification	Sorafenib	Predictive	D	Supports Sensitivity Response	2	submitted	EID9113 Through the histological examination of 25 patient tumor samples with hepatocellular carcinoma, the efficacy of postoperative sorafenib treatment may be correlated with higher levels of c-Raf-1 expres… (full text at CIViC) PMID 26981887 · Lei et al., 2016 · Open in CIViC	civic